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Introduction
Despite being a relatively rare cancer, pancreatic ductal 
adenocarcinoma (PDAC) has recently become the third 
highest cause of death in females worldwide, having 
overtaken the much more prevalent breast cancer (1). 
It is also the 4th commonest cause of death in men and 
little impact has been made on improving survival over 
several decades (1). In the UK in 2010, 8,463 people were 
diagnosed with pancreatic cancer and there were 7,901 
deaths (1). Five year overall survival remains extremely low 
at approximately 5% (1). 
Surgery is possible in 10–20% of cases and with the 
evidence supporting a survival advantage with adjuvant 
chemotherapy—this is now the accepted standard of care. 
In an analysis of data from the ESPAC 3 (2) study, completion 
of six cycles of adjuvant chemotherapy was associated with 
doubling of median survival from 14 to 28 months but 
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unfortunately many patients fail to complete or even 
receive adjuvant therapy (2). In Scotland, an audit of 
treatment received for pancreatic cancer found that only 
55% of patients undergoing resection for pancreatic cancer 
received adjuvant therapy (3). In ESPAC 3, where patients 
were already sub-selected as suitable to be considered for 
chemotherapy, only 68% of patients completed all six 
cycles (2). 
Surgical resection is associated with positive resection 
margins in the majority of patients, and it is questionable 
whether primary resection is the appropriate approach in 
this group, where long term survival is rare. 
Prior to 2011, the absence of effective chemotherapy, 
with the possibility of a meaningful response, was a 
major barrier to the use of neo-adjuvant chemotherapy 
in pancreatic cancer. Response rates of only 3–9% were 
reported with gemcitabine or gemcitabine combinations 
and experience with other drug combinations was limited 
(4,5). The advent of more effective chemotherapy, with 
FOLFIRINOX in metastatic pancreatic cancer, signalled a 
change in direction. In this study, not only was meaningful 
improvement in survival achieved, radiological response 
was seen in 30% of cases improvement in survival (11.1 vs. 
6.8 months, P<0.001) (6).
Since then, there has been increasing interest in the use 
of FOLFIRINOX and other drug combinations in the neo-
adjuvant setting, primarily for patients with borderline or 
irresectable disease where down-staging is desirable. There 
has also been some early experience with FOLFIRINOX 
in resectable pancreatic cancer, albeit in highly selected 
groups (7-9).
FOLFIRINOX is perceived as a toxic regimen. It was 
not widely adopted in the UK (and is still not used in many 
centres) and we were therefore keen to record toxicity in the 
non-metastatic group. This also provided an opportunity to 
explore efficacy in the LAPC group as the original clinical 
trial had been in metastatic patients only (6). 
In 2012, following discussions in our MDT, we devised 
a protocol utilising FOLFIRINOX (FFX) in the non-
metastatic pancreatic cancer setting. The primary aim of 
this study was to evaluate the effect on overall survival, 
radiological response, pathological response and to define 
the tolerability of this approach both from toxicity from 
chemotherapy and surgical morbidity. For patients who 
could not be treated with FFX, but were fit for combination 
chemotherapy, we offered Gemcitabine Capecitabine 
(GemCap) as induction chemotherapy and we collected the 
same data for these patients. 
Methods
This was a retrospective analysis of a prospectively maintained 
database. Patients from 2012 to 2015 referred to the 
West of Scotland Regional Hepato-Pancreatic Biliary 
(HPB) MDT were included in this cohort. Prior to 2012, 
patients with resectable disease were treated with surgical 
resection followed, where possible, by adjuvant gemcitabine 
chemotherapy. Patients with localized borderline resectable 
or irresectable tumours were managed by gemcitabine 
chemotherapy. 
Following 2012, patients with localized pancreatic cancer 
were stratified into four groups as detailed below. Our 
staging algorithm included, CT scan of chest, abdomen 
and pelvis within 6 weeks of surgery. In 2013, for patients 
without liver metastases on CT, we introduced an MRI 
liver with gadolinium contrast. This time period also 
spanned recruitment to the PET PANC (10) study where 
patients were also given PET CT as part of a prospective 
UK study. Endoscopic ultrasound was used for clarification 
of distant lymph node metastases and for tissue diagnosis in 
the majority of cases. 
When staging was complete all patients were discussed 
at the regional MDT, classified according to resectability 
criteria and a treatment plan agreed. Where patients were 
deemed surgically resectable (A or B by the definitions in 
Table 1), formal cardiovascular fitness testing (CPET) was 
carried out. Patients managed by a “surgery first” approach 
are excluded from the current analysis. These represented 
Table 1 Chemotherapy regimens (chemotherapy was given with G-CSF days 5–10)
Regimen Drugs Dose (mg/m
2
) Days Duration (days)
FOLFIRINOX (FFX) (11) Oxaliplatin; Irinotecan; 
5-Flurouracil; 5-Flurouracil
85;
 
180; 400; 2,400 D1; D1; D1; D1–2 14
Gemcitabine Capecitabine (GC) (12) Gemcitabine; Capecitabine 1,000; 830 BD D1, 8,15; D1–21 28
Following initial experience and confidence with FOLFIRINOX, we introduced chemo-radiotherapy into both chemotherapy protocols. 
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a heterogeneous group with either tumours staged as “A”, 
tumours thought to arise in IPMN or patients in whom a 
tissue diagnosis was not obtained despite EUS FNA/FNB. 
Our criteria for resectability are those of the NCCN 
guidelines (13):
(I) No distant metastases;
(II) Venous involvement of the SMV or PV with 
distortion or narrowing of the vein or occlusion of 
the vein widths suitable vessel proximal and distal, 
allowing safe resection and reconstruction;
(III) Gastro-duodenal artery encasement up to hepatic 
artery with either short segment encasement or 
direct abutment of the hepatic artery, without 
extension to the celiac axis;
(IV) Tumour abutment of the SMA not to exceed 
greater than 180° of the circumference of the vessel 
wall.
Locally we have adapted these guidelines to assist in our 
regional MDT decision-making process (Figure 1). 
Chemotherapy protocol (2012–2015)
Fit patients under 70 years of age were offered FFX. In 
patients deemed unfit for triplet therapy or over 70 years 
Clinical 
Evaluation Imaging Criteria Category Management
Resection with 
potential for R0
Small Tumour (≤T2) 
with no proximity to 
vessel
A Surgery
Operable but 
likely R1 
resection
T3 tumour adjacent to 
SMV or short segment 
narrowing / adjacent to 
SMA/HA (no 
deformation)
B
Neoadjuvant 
chemotherapy 
+ ChemoRT Inoperable but 
would be 
candidate for 
resection if 
significant 
downstaging 
response
T3 tumour adjacent to 
vessels including 
significant narrowing or 
SMA/HA contour 
deformation (<1800)
C
Best 
supportive 
care
Inoperable and 
will never be a 
resection 
candidate
T3/T4 with long segment 
SMV narrowing/occlusion or 
SMA/HA contour deformation 
(>1800)
or
Metastatic Disease
D1
Palliative 
Treatment
Unfit
Any of the above E
D2
Figure 1 Definitions of resectability: Glasgow resection criteria.
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of age Gemcitabine/Capecitabine (GemCap) (11) was 
used (doses outlined in Table 1). A re-staging CT Chest 
Abdomen and Pelvis scan was performed to assess tumour 
response and resectability after 3 months of chemotherapy 
(either 6 cycles of FOLFIRINOX or 3 cycles of GemCap). 
At this juncture, the multidisciplinary team assessed the 
radiological response to treatment. 
Chemoradiotherapy 
Patients who had stable disease or better on a CT Chest 
Abdomen Pelvis approximately 4 weeks after completion 
of chemotherapy were considered for chemoradiotherapy 
(CRT). This comprised Volumetric Modulated Arc Therapy 
delivering 50.4 Gy in 28 fractions over 5.5 weeks with 
concurrent Capecitabine as per the SCALOP trial (11). 
Subsequently, if patients were considered potentially 
resectable, surgical exploration was undertaken. Two 
radiologists evaluated radiological response to chemotherapy 
prospectively as part of the multidisciplinary assessment. 
We predicted from other retrospective series and also 
from peri-operative regimens in other tumour types—a 
progression rate of approximately 30% (12,14,15), and for 
these patients, second line chemotherapy, a clinical trial or 
best supportive care were considered, as appropriate.
Surgical resection
Where appropriate, patients underwent surgical resection 
in the West of Scotland Pancreatic Unit, Glasgow Royal 
Infirmary, and Glasgow, UK. Classical or pylorus-
preserving pancreaticoduodenectomy, total or distal 
pancreatectomy, were performed by four surgeons (CRC, 
CJM, EJD and DKC). Surgical approach was unaltered 
through the study period. Briefly, following full laparotomy 
the right colon was fully mobilized and rotated to allow 
exposure of the intrapancreatic superior mesenteric vein. 
The duodenum was Kocherised clearing retroperitoneal 
and aortocaval lymphatics en bloc. The common hepatic 
duct was transected just below the portal confluence and the 
common hepatic artery cleared of lymphatics to its origin at 
the coeliac axis. Patients were usually managed by an “artery 
first” approach with complete exposure of the superior 
mesenteric artery and division of the superior and inferior 
pancreaticoduodenal branches before pancreatic and either 
duodenal or gastric transection. Following transection of 
the first jejunal loop and division of the mesentery, the 
duodenum and proximal jejunum were rotated posteriorly 
and dissection from the superior mesenteric/portal vein 
completed. Venous involvement was managed by vein 
resection and either primary repair or autologous vein 
graft as appropriate. Reconstruction was by single loop 
duodeno/gastro-jejunostomy, pancreaticojejunostomy or 
pancreaticogastrostomy and hepaticojejunostomy. Post-
operative management was defined by an ERAS protocol.
Adjuvant chemotherapy protocol (2009–2012)
Following publication of the ESPAC 3 study (2), like 
many centres, the West of Scotland HPB Unit, adopted 
Gemcitabine 1,000 mg/m2 D1, 8, 15 q28 as its adjuvant 
regimen of choice. 
Pathology assessment 
During the study period, resection specimens were 
assessed by two specialist gastrointestinal pathologists 
with a specialist interest in pancreatic disease. Microscopic 
pathological assessment and reporting included: maximum 
tumour diameter and extent and location of local spread, 
tumor grade, perineural, venous, and lymphatic invasion, 
total of lymph nodes examined and number positive. 
For this study, tumor grade was categorized as either high 
(for poorly differentiated tumors) or low (for moderately 
and well-differentiated tumors). On receipt of the specimen, 
the four pancreatic margins (pancreatic transection, medial, 
posterior and anterior surface) were identified and inked 
with different colours. Full details of the pathological 
assessment have been detailed previously (16).
Current guidelines define margin positivity as the 
presence of tumor at within 1 mm of a margin when 
assessed by microscopy of a hematoxylin-and-eosinophil 
stained slide.
Toxicity assessment 
Toxicity was graded according to the CTC version 4 (17). 
All postoperative complications were prospectively recorded 
in a surgical outcomes database and graded through 
detailed weekly consensus discussion by the four operating 
pancreatic surgeons according to the International Study 
Group of Pancreatic Surgery (ISGPS) classifications and 
the Clavien-Dindo classification (18).
Statistics
All statistical testing was conducted at the 5% level so 95% 
confidence intervals (CI) are reported throughout. Unless 
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Neoadjuvant chemotherapy
Folfirinox =65 (76.5%)
Gem/Cap = 20(23.5%)
Localised PDAC (n=85)
A=0
B=45 (52.9%)
C=19 (22.3%)
D=19(22.3%)
Multi-visceral =2 (2.5%)
ChemoRT
35/85 (41.2%) Surgery17/85 (20%)
Progression or 
unsuitable for 
further treatment
33/85(38.8%)
Surgery
17/35 (48.6%)
Progression or 
unsuitable for 
further treatment
18/35 (51.4%)
Adjuvant Gemcitibine
12/17 (70.5%)
Median 4 cycles (3-6)
Adjuvant Gemcitibine
8/17 (47%)
Median 6 cycles (1-6)
Figure 2 Consort diagram all patients. Multimodality treatment: lines of treatment all non-Metastatic patients.
otherwise stated, medians and interquartile range (IQR) 
are used. The survival time defined as the number of 
months from study entry until death or if alive at follow-
up date, was calculated. Univariate survival analysis was 
carried out using Kaplan-Meier method and the log rank 
test. Survival analysis was carried out using the Cox’s 
proportional-hazards model and hazard ratios (HR) were 
calculated. Multivariate survival analysis was performed 
using a stepwise backward procedure to derive a final 
model of the variables that had a significant independent 
relationship with survival. To remove a variable from the 
multivariate model, the corresponding P value had to be 
>0.20. 
Statistical analyses were performed using SPSS v21.0 
(SPSS Inc., Chicago, IL).
Results
Baseline characteristics
In total 85 patients were included in the study. The patients 
are shown in the consort diagram below (see Figure 2).
The median age was 65 (range 42–79) years and the 
majority were male with good performance status, and as 
per our local protocol were offered FFX chemotherapy 
as their induction chemotherapy regimen. Baseline 
characteristics are described in Table 2 below.
Toxicity in all non-metastatic patients (N=85)
FOLFIRINOX group
A total of 65 patients underwent chemotherapy with FFX. 
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Table 3 outlines the patient characteristics. Thirty three 
(50.8%) completed 6 cycles as planned, 19 (29.2%) stopped 
chemotherapy early and 13 (20%) underwent further cycles 
(up to a maximum of 12). Fifteen (23.1%) patients started 
with a dose reduction. In total 40 (61.5%) required a dose 
reduction during their treatment. The majority of patients 
had at least one treatment delay (43, 66.1%) with 3 patients 
requiring their treatment to be stopped. All patients were 
treated with prophylactic Granulocyte Colony Stimulating 
Factor (GCSF day 5–10 sc 30,000 iU).
FFX was wel l  tolerated.  The commonest  were 
haematological and gastrointestinal with 2 patients having 
febrile neutropenia (3.1%). Notably 20 (30.8%) of patients 
had weight loss of greater than 10% of baseline body 
weight. Of the 3 deaths 2 were attributed to pneumonia and 
sepsis in patients with pre-existing comorbidity while the 
other was due to rapid progression of cancer.
Table 2 Baseline characteristics (n=85)
Characteristic Number (%)
Gender
Male 47 (55.3%)
Female 38 (44.7%)
Age
Median (range) 65 [42–79]
Resectability criteria
B 45 (53.0%)
C 19 (22.4%)
D1 19 (22.4%)
Multivisceral 2 (2.4%)
Tumour site
Body/tail 12 (14.1%)
Uncinate 9 (10.6%)
Head 45 (52.9%)
Neck 19 (22.4%)
PS
0 46 (54.1%)
1 37 (43.5%)
2 2 (2.4%)
Chemotherapy regimen
FFX 65 (76.5%)
GC 20 (23.5%)
FFX, FOLFIRINOX; GC, Gemcitabine Capecitabine.
Table 3 FOLFIRINOX group baseline characteristics (n=65)
Baseline characteristics/toxicity Number (%)
Three months chemo delivered
Yes 33 (50.8)
No 19 (29.2)
Additional cycles 13 (20.0)
Dose reduction @ cycle 1
Yes 15 (23.1)
No 50 (76.9)
Later cycle dose modification
Yes 42 (64.6)
No 23 (35.4)
Maximum dose delays
No 22 (33.8)
<1 week 26 (40.0)
>1 week 14 (21.5)
Chemo discontinued 3 (4.6)
Haematological tox (G3/4)
3 5 (7.7)
4 2 (3.1)
Biochem (G3/4)
3 2 (3.1)
Diarrhoea
3 6 (9.2)
Nausea/vomiting
3 3 (4.6)
Fatigue
3 5 (7.7)
Sepsis
3 2 (3.1)
Weight change(missing =2)
Nil (or gain) 17 (26.2)
<5% 12 (18.5)
5–10% 14 (21.5)
>10% 20 (30.8)
Post chemo albumin
>30 49 (75.4)
25–29 12 (18.5)
20–24 4 (6.2)
CT response (missing =1)
PR 11 (16.9)
SD 34 (52.3)
PD 16 (24.6)
Death 3 (4.6)
PR, partial response; SD, stable disease; PD, progressive disease.
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Table 5 CRT group (n=33)
Concurrent chemotherapy regimen Number (%)
Chemotherapy regimen
Capecitabine 31 (93.9)
Gemcitabine 2 (6.1)
Chemotherapy completed
Yes 31 (93.9)
No 2 (6.1)
Table 4 Gemcitabine/Capecitabine group baseline characteristics 
(n=20)
Baseline characteristics/toxicity Number (%)
Three months chemo delivered
Yes 14 (70.0)
No 4 (20.0)
Additional cycles 2 (10.0)
Dose reduction @ cycle 1
No 20 (100.0)
Later cycle dose modification
Yes 10 (50.0)
No 10 (50.0)
Maximum dose delays
No 16 (80.0)
<1 week 2 (10.0)
>1 week 1 (5.0)
Chemo discontinued 1 (5.0)
Haematological tox (G3/4)
3 2 (10.0)
Fatigue
3 1 (5.0)
Weight change (missing =5)
Nil (or gain) 8 (40.0)
<5% 5 (25.0)
5–10% 1 (5.0)
>10% 1 (5.0)
Post chemo albumin
>30 17 (85.0)
25–29 2 (10.0)
20–24 1 (5.0)
CT response (missing =1)
PR 1 (5.0)
SD 12 (60.0)
PD 6 (30.0)
Death 1 (5.0)
PR, partial response; SD, stable disease; PD, progressive disease.
Gem/Cap group
Table 4 outlines baseline characteristics of group of patients 
who received GEMCAP chemotherapy. Twenty patients 
received Gem/Cap chemotherapy due to age or poor 
performance status, 14 (70%) completed the planned 3 
months of chemotherapy with 4 having less than planned 
and 2 having additional cycles. No patients started with 
a dose reduction. Ten (50%) required a dose reduction 
during their chemotherapy course with 4 (20%) having 
some dose delay. Only 1 (5%) required discontinuation of 
chemotherapy. Significant toxicity was very modest with 
only 3 patients having any G3/4 toxicity. Only 1 (5%) 
patient had weight loss of greater than 10% of their body 
weight. The cause of death in the 1 patient was cancer 
progression and cachexia.
CRT group
In total 33 (38.8%) patients underwent CRT as part of their 
treatment protocol and details are outlined in Table 5 below. 
All patients completed the full course of radiotherapy. 
Two patients (6.1%) stopped the chemotherapy early 
due to toxicity (1 due to G3 weight loss and 1 due to G3 
diarrhoea). Both of the patients who stopped chemotherapy 
were being treated with capecitabine.
Efficacy
Resected group
Although locally advanced inoperable patients were 
included in this study (in order to record toxicity in the 
non-metastatic setting and calculate conversion rates) we 
were particularly interested in the tolerability and efficacy 
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in the group of patients with resectable pancreatic cancer 
(please see consort diagram, Figure 2). 
At the time the study started there were a small number 
of centres reporting efficacy in patients with borderline 
resectable tumours. The effect of FOLFIRINOX and 
chemo-radiotherapy on smaller, resectable tumours both in 
terms of response and influence on surgical morbidity was 
unknown (Figure 3).
Outcome in the surgical sub group of patients
Forty five patients, following initial staging by CT 
CAP, MRI liver and EUS in the majority of cases, were 
considered to be potentially surgically resectable. Following 
induction chemotherapy and then chemo-radiotherapy 
if stable, 34 patients remained potentially operable. In 
2 of cases there was previously unidentified evidence of 
metastatic disease found at operation and surgical bypass 
was carried out. In resected patient, pathological stage 
(Table 6) appeared to be most favourable in the group who 
had undergone chemotherapy, followed by CRT, however 
the result was not statistically significant and this was most 
likely because of the small sample size. 
The same was seen for resection margin status (Table 7).
Overall survival
The median follow up for survivors was 21.2 (11.2– 
37.1) months. The median overall survival was 17.9 (13.2–
22.6) months. The 12-month survival rate was 54% (SE 
6%).
Median survival was 22.2 months in the potentially 
resectable group, very similar to the ESPAC 3 data 
previously discussed. It should be noted however that this 
group included those patients who did not proceed to 
Neoadjuvant	chemotherapy
Folfirinox	=35	(77%)
Gem/Cap	=	8(23.%)
LocalisedPDAC	 (n=85)
B=45	(52.9%)
Multi-visceral	=2	(2.5%)
ChemoRT
20/45	(44.4%)
Surgery
14/45	(31.1%)
Progression	or	
unsuitable	for	
further	treatment
Palliative	
chemotherapy	8	
(17.8%)
Supportive	Care	3	
(6.7%)Surgery
16/20	(80%)
Progression	or	
unsuitable	for	
further	treatment
4/20	(20%)
Adjuvant	Gemcitibine
12/16	(75%)
Median	4	cycles	(3-6)
Adjuvant	Gemcitibine
8/14	(57%)
Median	4	cycles	(1-6)
Figure 3 Consort diagram surgical patients. Multimodality treatment: lines of treatment for patients when surgery was planned from the outset.
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surgery. Survival for patients proceeding to resection was 
37 months.
The number of initially inoperable patients with C or D1 
disease who could be down-staged to a resectable situation 
was only 3/19 (15.8%). 
Location of primary tumour and weight loss during 
induction chemotherapy did not appear to impact 
on survival but pre-operative performance status and 
radiological tumour stage were significant determinants 
of survival on univariate analysis, with earlier tumours 
achieving the best results with neo-adjuvant treatment 
(Tables 8,9, Figure 4).
In the subgroup of patients undergoing surgical resection, 
survival was 37 months for patients initially thought 
resectable (B). For those with initially irresectable disease 
in whom down-staging was achieved and who proceeded 
to resection, survival was disappointing at 11.5 months 
(Table 10, Figure 5).
Survival for surgical patients
At time of data censoring April 29th 2016, 18/34 surgical 
patients were alive (56%). Median survival was 37.0 months 
(95% CI, 18.2–55.7).
We next examined whether the pre-operative treatment 
we delivered influenced the post-operative pathology 
Table 6 Comparison of post-op stage by TNM classification between pre-op CRT and no pre-op CRT (P=0.424)
TNM stage
Subsequent treatment following chemotherapy
Total (n=34)
CRT + surgery (n=17) Surgery alone (no CRT) (n=17)
T0N0 3 (17.6%) 0 3 (8.8%)
T1N0 3 (17.6%) 2 (11.8%) 5 (14.7%)
T3N0 5 (29.4%) 3 (17.6%) 8 (23.5%)
T4N0 0 1 (5.9%) 1 (2.9%)
T1N1 1 (5.9%) 1 (5.9%) 2 (5.9%)
T2N1 1 (5.9%) 1 (5.9%) 2 (5.9%)
T3N1 4 (23.5%) 6 (35.3%) 10 (29.4%)
T4N1 0 1 (5.9%) 1 (2.9%)
M1 0 2 (11.8%) 2 (5.9%)
TNM, tumour nodes metastasis; CRT, chemoradiotherapy.
Table 7 Comparison of margin status between pre-op CRT and no pre-op CRT (P=0.169)
Margin status
Subsequent treatment
Total (n=32)
CRT + Sx (n=17) Sx (no CRT) (n=15)
R0 12 (70.6%) 7 (46.7%) 19 (59.4%)
R1 5 (29.4%) 8 (53.3%) 13 (40.6%)
Total 17 15 32
CRT, chemoradiotherapy.
Table 8 Stage dependent survival, including patients not undergoing 
resection (P=0.001)
Baseline resection 
category
Number
Median survival  
months (95% CI)
B 45 22.2 (18.8–25.5)
C 19 18.5 (9.3–27.7)
D1 19 9.0 (6.9–11.0)
Multi-visceral 2 10.6 (–)
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Table 9 Hazard ratio for survival based upon baseline characteristics
Parameter Patients (N) Univariate [HR (95%CI)] P value
Sex 0.211
Male 47 1
Female 38 0.71 (0.41–1.22)
Chemo regimen (6 switched from FFX to Gem/Cap) 0.314
FFX 59 1
GC 20 1.39 (0.72–2.67)
Performance status 0.002
0 46 1
1 37 1.81(1.05–3.12)
2 2 27.2(5.25–147.7)
Baseline resection category 0.003
B1 18 1
B2 27 1.86 (0.76–4.56)
C 19 2.67 (1.08–6.59)
D1 19 4.85 (1.97–11.9)
Multivisceral 2 7.20 (1.46–35.9)
Tumour location 0.514
Body 12 1
Uncinate 9 1.66 (0.62–4.45)
Head 45 0.96 (0.44–2.11)
Neck 19 0.82 (0.33–2.01)
Weight change during chemo 0.861
Nil 25 1
<5% 17 1.01 (0.47–2.19)
5–10% 15 0.98 (0.40–2.41)
>10% 21 1.30 (0.67–2.52)
Albumin post chemo 0.167
≥30 66 1
25–29 14 1.92 (0.98–3.78)
20–24 5 1.57 (0.55–4.45)
specimen. We observed a statistically significant difference 
in LVI and less PNI and this fitted with the trend towards 
smaller sized tumour’s with a lower number of node positive 
tumour’s and also the reduced number of R1 cancers 
(previously described in Table 7).
Discussion
Our paper demonstrates the deliverability of a complex 
chemotherapy protocol in a cohort of patients with localized 
pancreatic cancer in the West of Scotland. It builds upon 
the current limited published data and also demonstrates 
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that both FOLFIRINOX and chemo-radiotherapy can be 
delivered safely in the neo-adjuvant setting with acceptable 
levels of toxicity. The current ESPAC 5F study in the UK 
includes such regimes and it is of value to both the UK 
and wider clinical communities to see the impact of these 
regimes.
Only 19 patients (29.2%) stopped chemotherapy early in 
the FOLFIRINOX arm. Similarly 16 of 20 patients in the 
GEMCAP arm received all the planned cycles. 
We were initially concerned about the impact of 
adjuvant gemcitabine chemotherapy in patients undergoing 
resection following neo-adjuvant chemotherapy and chemo-
radiotherapy but found this to be well tolerated. The 
proportion of patients who received adjuvant chemotherapy 
was 66% overall. This is slightly higher than that reported 
in other adjuvant trials such as ESPAC 3 (2), or real world 
data such as the Scottish HBC cancer network audit. 
One concern of a neo-adjuvant approach is the potential 
for patients to progress during this neoadjuvant phase and 
thus miss out on the possibility of surgery. However in our 
intention to treat cohort we demonstrate a median survival 
of 22 months, which is very similar to the median survival 
in the ESPAC 3 study. This indicates no overall detriment 
to patients treated by this algorithm. In addition it could be 
argued that avoiding futile surgery in those patients with 
very aggressive disease is in fact a benefit. Survival in the 
cohort of patients who progressed on neoadjuvant therapy 
was similar to that of patients not receiving adjuvant 
chemotherapy in the ESPAC III study (this data is not 
included in the paper).
Chemo-radiotherapy was well tolerated with all patients 
completing their radiotherapy and only two requiring 
their chemotherapy to stop early. This compare is very 
favourably with the recent SCALOP (11) study in which 
29/72 patients had to stop radiotherapy early. This is likely 
to be a clear manifestation of advances in radiotherapy 
planning/delivery techniques as all of our patients group 
had their radiotherapy delivered with VMAT significantly 
reducing the radiation dose to regional organs at risk such 
as duodenum and liver and in addition our cohort included 
more earlier stage smaller tumours.
In the landmark ESPAC 3 (2) study the majority of 
patients had relatively high stage of disease with T3 N1 
being by far the commonest pathological outcome. Only 
around 10 % had stage I disease. In our resected cohort 
Table 10 Stage-dependent survival for those undergoing radical 
resection (P<0.001)
Baseline resection 
category
Number
Median survival  
months (95% CI)
B 30 37.0 (18.2–55.7)
C 3 11.5 (8.8–14.2)
D1 0 –
Multi-visceral 1 6.9 (–)
Figure 4 The relationship between stage (B vs. C vs. D from top 
to bottom) and survival in all patients (log rank P<0.001). 
Figure 5 The relationship between stage (B vs. C from top 
to bottom) and survival in all patients who underwent radical 
resection (log rank P<0.001). 
1.0
0.8
0.6
0.4
0.2
0.0
0.00             10.00             20.00             30.00             40.00
Survival (months)
C
um
 s
ur
vi
va
l
1.0
0.8
0.6
0.4
0.2
0.0
0.00             10.00             20.00             30.00             40.00
Survival (months)
C
um
 s
ur
vi
va
l
694 Grose et al. Neoadjuvant therapy in pancreatic cancer
© Journal of Gastrointestinal Oncology. All rights reserved. J Gastrointest Oncol 2017;8(4):683-695jgo.amegroups.com
8/34 (23.5%) had either T0N0 or T1N0 with 60% across 
the cohort having an R0 margin. It is hoped that with long-
term follow we will demonstrate far better outcomes with 
such favourable pathology.
Our conversion rate of 15.8% is lower than that quoted 
in previous single centre experiences where rates of up 
to 30% have been reported (19). Via our classification a 
“B” tumour would be considered operable but with a high 
chance of positive margins or involved locoregional lymph 
nodes whereas a “C” was considered borderline resectable 
with a response to neoadjuvant treatment required for 
surgery to be considered. All of the patients classified as 
“C” had long segment SMV/portal vein involvement or 
significant (up to 180°) involvement of the SMA and were 
patients in whom surgical exploration would not have been 
attempted in our institution prior to the introduction of the 
neoadjuvant protocol. It is likely that some of the patients 
staged as “B” within our series would have been classed as 
borderline resectable in other series. The poor prognosis 
of patients initially staged as “C” in whom downstaging 
was achieved suggests that consideration should be given 
to accepting chemotherapy (± chemoradiotherapy) as 
definitive treatment regardless of response. This is certainly 
our approach to patients with proven metastatic disease at 
presentation. Clearly there are no randomized data to direct 
management of patients with “C” or D1’ tumours who 
respond to systemic therapy (11).
The number of patients treated remains small but in 
our experience at least, patients with initially inoperable 
disease are rarely downstaged and following surgical 
resection, survival was no better than for similar patients 
treated by chemoradiotherapy alone. Importantly the group 
that had the greatest survival was the B’s who managed 
the full treatment protocol. To our knowledge this is the 
most promising survival data for this cohort of patients 
and suggests that targeting earlier staged tumours i.e., 
potentially operable disease may offer some of the greatest 
benefits with the neo-adjuvant approach
Conclusions
In conclusion we have described a novel approach to 
localized pancreatic cancer patients in the west of Scotland. 
We have also demonstrated the potential benefits of 
chemotherapy and chemo-radiotherapy delivered in a neo-
adjuvant setting including more favourable pathology, 
improved R0 rates and an indication of improved survival 
within the confines of acceptable toxicity. This work 
supports the aim of current neo-adjuvant studies such 
as ESPAC 5F but also goes further as it describes the 
combination of neo-adjuvant chemo + CRT not available 
within ESPAC 5F and extends experience to patients with 
initially resectable disease. 
This paper has demonstrated encouraging survival 
in patients undergoing resection following neoadjuvant 
therapy. No study of adjuvant therapy has come close to 
demonstrating median survival of 37 months in pancreatic 
cancer. The PRIMUS 002 study, which was recently 
funded, and will be led by our centre will take these early 
clinical observations and attempt to correlate with a deeper 
pre- clinical understanding. In this novel neoadjuvant trial 
patients will have serial biopsies, with molecular profiling, 
and we will aim to identify the exceptional responders—
but perhaps even more importantly the 30–50% who do 
not benefit from standard chemotherapy regimens and for 
whom alternative therapeutic options may become available 
in the future. 
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